Venture Partners and EIRs

Nessan Bermingham, PhD

Nessan has over ten years of experience in life science investing across venture, secondary, and public markets. Prior to joining Atlas, Nessan was a partner at Omega Funds and founder of Bio Equity Capital, a healthcare focused special situations firm. Nessan is co-founder of Ascelegen and Tal Medical, and sits on the advisory board of the California Institute for Regenerative Medicine.

Michael Curtis, PhD

Mike is chief development officer of Ataxion.  Prior to joining Atlas, Mike spent over twenty years in pharma, working in research and development roles at Bristol-Myers Squibb and Infinity Pharmaceuticals among others.  He has led multidisciplinary research and development teams, and advanced eight compounds from discovery to clinical studies across several therapeutic areas.  In addition, Mike was involved with advancing four compounds through late stage development resulting in three regulatory approvals.

Adam Friedman, MD, PhD

Adam is a member of the founding teams of Ascelegen, Raze Therapeutics, and Thew and also worked with the founding team at RaNA Therapeutics. He is also a research fellow at Massachusetts General Hospital, and was previously a physician at Boston Children's Hospital.

Michael Gilman, PhD

Mike is chief executive officer of Padlock Therapeutics.  Prior to joining Atlas, he founded Atlas portfolio company Stromedix, which was sold to Biogen Idec in 2012. Previously, he led all discovery research activities at Biogen Idec.  Before that, Mike served as chief scientific officer of ARIAD Pharmaceuticals and on the scientific staff at Cold Spring Harbor Laboratory.

Martin Jefson, PhD

Marty is chief scientific officer and co-founder of Rodin Therapeutics and Ataxion.  Prior to joining Atlas, Marty spent 27 years at Pfizer, most recently serving as head of neuroscience research. More than 30 development candidates were discovered during his tenure, including veranicline (Chantix), a widely used product for the treatment of nicotine addiction.

Ankit Mahadevia, MD

Ankit is co-founder, president, and chief business officer of Spero Therapeutics, co-founder and chief business officer of Rodin Therapeutics, and president of Synlogic.  Prior to joining Atlas, Ankit worked in business development at Genentech, in health policy in Washington, and helped build several early stage biotech companies including Arcion Therapeutics.  

Kevin Pojasek, PhD

Kevin is president, chief operating officer, and co-founder of Quartet Medicine and chief operating officer of Annovation Biopharma. Prior to joining Atlas, Kevin spent ten years in executive leadership and research and development roles in venture-backed startups, most recently serving as vice president of corporate development at Kala Pharmaceuticals.

Joshua Resnick, MD

Josh is co-founder and chief executive officer of Ataxion, and previously served on the board of CoStim Pharmaceuticals, which was sold to Novartis in February 2014. He is also an attending physician in emergency medicine at Brigham and Women's Hospital as well as an instructor at Harvard Medical School.  Prior to joining Atlas, Josh was a partner at Prism Ventures.

Eddine Saiah, PhD

Eddine is involved in multiple early stage projects for Atlas, and currently serves as head of chemistry at Raze Therapeutics and Quartet Medicine. Prior to joining Atlas, Eddine worked at Pfizer, where he most recently led chemistry efforts within the inflammation and immunology research unit as well as the orphan and genetic diseases group. Previously, Eddine was head of medicinal chemistry at Wyeth's Cambridge site.

Vipin Suri, PhD

Vipin is the head of biology of Raze Therapeutics, co-founder of NiDares, and consulting biologist for a number of Atlas seed investments. Prior to joining Atlas, Vipin was director and head of pharmacology at Sirtris, a GlaxoSmithKline company, and before that he worked in the cardiovascular and metabolic diseases group at Pfizer.